Last mentioned: 19h ago
Monash IVF cuts FY26 profit guidance to $17-18M, citing a 4.7% drop in ART cycles, while fending off a $0.90 takeover bid. The financial story now hinges on cost-cutting, international growth, and the possibility of a renewed offer.
Monash IVF’s profit downgrade and a high-profile embryo mix-up signal deeper turmoil in Australia’s ART market, with biotech and pharma implications for fertility drug and device manufacturers.
Monash IVF's profit warning exposes a 4.7% drop in stimulated IVF cycles, raising alarm over patient affordability and the sustainability of Australia's fertility care infrastructure. As the second-largest provider tightens its belt, clinics may face quality-of-care tradeoffs amid softening demand.